Last reviewed · How we verify
ALXN2220
ALXN2220 is a monoclonal antibody that targets phosphatidylserine on apoptotic cells to enhance their clearance and reduce neuroinflammation.
ALXN2220 is a monoclonal antibody that targets phosphatidylserine on apoptotic cells to enhance their clearance and reduce neuroinflammation. Used for Parkinson's disease, Alzheimer's disease (exploratory).
At a glance
| Generic name | ALXN2220 |
|---|---|
| Sponsor | Neurimmune AG |
| Drug class | Monoclonal antibody |
| Target | Phosphatidylserine |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | Phase 3 |
Mechanism of action
ALXN2220 binds to phosphatidylserine exposed on the surface of apoptotic cells, promoting their recognition and clearance by macrophages and microglia. By enhancing the removal of dying cells and reducing associated neuroinflammatory responses, the drug aims to slow neurodegeneration in conditions characterized by excessive cell death and microglial activation.
Approved indications
- Parkinson's disease
- Alzheimer's disease (exploratory)
Common side effects
- Infusion-related reactions
- Headache
- Fatigue
Key clinical trials
- Study of ALXN2220 Versus Placebo in Adults With ATTR-CM (PHASE3)
- Study of Re-Treatment With ALXN2220 in Patients With ATTR-CM (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ALXN2220 CI brief — competitive landscape report
- ALXN2220 updates RSS · CI watch RSS
- Neurimmune AG portfolio CI